We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




LumiraDx C-Reactive Protein (CRP) Test Achieves CE Marking

By LabMedica International staff writers
Posted on 21 Feb 2022

LumiraDx (London, UK) has achieved CE Marking for its C-reactive protein (CRP) Test, a small, portable, fully automated, microfluidic immunoassay test used for the quantitative determination of C-reactive protein with results within four minutes. More...

The measurement of CRP provides important information for the detection and evaluation of infection, and inflammation. In patients with respiratory infection symptoms, especially suspected pneumonia1, significantly high CRP suggests the need for antibiotic treatment, whereas normal or low CRP levels suggest patients have viral or self-limiting infection that does not require antibiotics. The LumiraDx CRP Test accurately measures direct fingerstick, venous whole blood, and plasma samples within a range of 5.0 - 250.0 mg/L. The assay is run on the LumiraDx Platform, which can be used at the patient side in primary and community care, patient homes and in hospital emergency care settings providing fast, reliable test results for timely decision making.

Clinicians can use the LumiraDx CRP test in the assessment of infection, tissue injury, and inflammatory conditions. Insights from the test can also provide valuable information to reduce unnecessary antibiotic prescribing, in an overall effort to fight antimicrobial resistance. In fact, while the consumption of antibiotics in England declined during the pandemic, recent studies have highlighted high rates of antibiotic prescribing among COVID-19 patients illustrating the unnecessary use of antibiotics and fear that antibiotic-resistant infections may return to pre-pandemic levels. Shipments of the LumiraDx CRP Test will begin shortly. The announcement comes on the heels of the company announcing the CE Mark for the LumiraDx SARS-CoV-2 & Flu A/B Antigen Test just last month.

"The addition of CRP onto the LumiraDx Platform will be critical this respiratory season to provide clinicians with a variety of tools to aid in the assessment of patients and their need for antibiotic treatment," said Ron Zwanziger, LumiraDx Chairman and CEO. "Including the assay on the LumiraDx platform along with our COVID-19 and Flu A/B tests will enable clinicians to make important treatment decisions at the point of care."

"Antimicrobial resistance is a growing concern across the globe, and if left unaddressed will lead to a serious public health crisis. While the causes of antimicrobial resistance are complex, growing evidence suggests that improving the clinical diagnosis of respiratory infections in patients is a key component in tackling unnecessary antibiotic prescribing rates," added Professor Jonathan Cooke, visiting Professor in the Department of Surgery and Cancer, Faculty of Medicine at Imperial College London. "Having access to rapid CRP-POCT diagnostic tools has been shown to support healthcare providers when making prescribing decisions and helps improve the management of respiratory infections."

Related Links:
LumiraDx 


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.